Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED has successfully raised c US$537m (or HK$4.17bn) through its Hong Kong IPO and global offering. The new funds enable management to execute their ambitious near- and medium-term growth plans. As well as progressing the second and third wave of innovative programmes through clinical trials, the proceeds will be used to bolster the China Oncology commercial organisation and further develop the equivalent global infrastructure. A sister note detailing the recent clinical data for the key late-stage assets is published alongside this note. We upgrade our valuation to US$8.84bn (US$52.12 per ADS), £6.8bn and HK$69.0bn (802p or HK$81.30 per share) to reflect the raise and recent clinical news.

Market information



A genuinely global R&D-driven biopharma business
Lighthouse | 03 Mar 2022
Strategic collaboration for Tazverik in Greater China
Lighthouse | 10 Aug 2021
ASCO 2021: Moving towards combinations
Update | 06 Jul 2021

Recent News

Tazverik approved in Hainan Pilot Zone in China
01 Jun 2022
CRL for surufatinib from US FDA
02 May 2022
Update on status under HFCAA
31 Mar 2022
2021 Annual Report and Notice of AGM
23 Mar 2022